Health & Fitness
Mon, April 22, 2013Sun, April 21, 2013Fri, April 19, 2013Thu, April 18, 2013Wed, April 17, 2013Tue, April 16, 2013Mon, April 15, 2013Fri, April 12, 2013Thu, April 11, 2013Wed, April 10, 2013Tue, April 9, 2013Mon, April 8, 2013Sat, April 6, 2013Fri, April 5, 2013Thu, April 4, 2013Wed, April 3, 2013Tue, April 2, 2013Mon, April 1, 2013Fri, March 29, 2013Thu, March 28, 2013Wed, March 27, 2013Tue, March 26, 2013Mon, March 25, 2013Sun, March 24, 2013Fri, March 22, 2013The Law Firm of Levi &;; Korsinsky Notifies Investors With Losses on Their Investment in Incyte Corporation of Class
//health-fitness.news-articles.net/content/2013/ .. r-investment-in-incyte-corporation-of-class.html
Published in Health and Fitness on Friday, April 5th 2013 at 11:46 GMT by Market Wire🞛 This publication is a summary or evaluation of another publication
April 05, 2013 14:34 ET
SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors With Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline
NEW YORK, NY--(Marketwired - Apr 5, 2013) - Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the District of Delaware on behalf of investors who purchased Incyte Corporation ("Incyte" or the "Company") (
For more information, click here: [ http://zlk.9nl.com/incyte-incy/ ].
According to the complaint, Incyte's reported fourth quarter 2011 and first quarter 2012 sales were artificially inflated due to a large number of advanced-stage myelofibrosis patients being prescribed the drug upon FDA approval in November 2011 -- patients who had been too sick to participate in the clinical trials.
On August 2, 2012, Incyte disclosed that Jakafi sales growth had been much softer during the second quarter of 2012 than investors had been led to expect. Defendants also disclosed that many of the new patients prescribed Jakafi were so sick they would not have been eligible for the Phase III trial. Defendants conceded that while prescriptions to these patients had increased sales revenues, these were not revenues that would continue for the suggested three years on average that defendants claimed, as certain patients died. In response to these disclosures, the price of Incyte stock fell from its August 1, 2012 close of $24.92 per share to close at $19.57 per share on August 2, 2012.
If you suffered a loss in Incyte you have until May 6, 2013 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. To obtain additional information, contact Joseph E. Levi, Esq. either via email at [ jlevi@zlk.com ] or by telephone at (877) 363-5972, or visit [ http://zlk.9nl.com/incyte-incy/ ].
Levi & Korsinsky is a national firm with offices in New York, New Jersey, and Washington D.C. The firm has extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.